» Articles » PMID: 11283530

Estimating the Prognosis of Hepatic Resection in Patients with Metastatic Liver Tumors from Colorectal Cancer with Special Concern for the Timing of Hepatectomy

Overview
Journal Surgery
Specialty General Surgery
Date 2001 Apr 3
PMID 11283530
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The effect of the time interval between colorectal and liver resection for metastatic lesions on the patient's survival remains controversial. Pretreatment classification for predicting the prognosis of this disease has not yet been reported.

Methods: Nine clinical factors revealed by preoperative examinations, intraoperative screening before liver resection, and resection margin were examined in 304 patients who underwent hepatic resections for metastatic colorectal carcinoma. The patients were divided according to the timing of hepatectomy and both tumor number and maximum diameter to devise a staging system.

Results: Tumor number and maximum tumor size were significant prognostic factors in the metachronous hepatectomy group, and resection margin was significant in the synchronous group. The following staging system was proposed: stage I, n < or = 3 and diameter < 5 cm in the metachronous hepatectomy group (n = 86); stage II, n < or = 3 and diameter > or = 5 cm in the metachronous hepatectomy group (n = 46); and stage III, n > or = 4 and diameter > 5 cm in the metachronous group and the synchronous hepatectomy group (n = 144).

Conclusions: The current study revealed that the factors that influenced the patient's prognosis were different between the synchronous and metachronous groups. It may be useful to develop a staging system that considers this difference.

Citing Articles

Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.

Kanas G, Taylor A, Primrose J, Langeberg W, Kelsh M, Mowat F Clin Epidemiol. 2012; 4:283-301.

PMID: 23152705 PMC: 3496330. DOI: 10.2147/CLEP.S34285.


Utility of preoperative imaging in evaluating colorectal liver metastases declines over time.

Yang S, Hongjinda S, Hanna S, Gallinger S, Wei A, Kiss A HPB (Oxford). 2010; 12(9):605-9.

PMID: 20961368 PMC: 2999787. DOI: 10.1111/j.1477-2574.2010.00202.x.


Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.

Liu J, Hsieh Y, Chen W, Hsu Y, Chau G, Teng H Int J Colorectal Dis. 2010; 25(10):1243-9.

PMID: 20574727 PMC: 2928445. DOI: 10.1007/s00384-010-0996-4.


Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.

Boostrom S, Nagorney D, Donohue J, Harmsen S, Thomsen K, Que F J Gastrointest Surg. 2009; 13(11):2003-9.

PMID: 19760306 PMC: 2813967. DOI: 10.1007/s11605-009-1007-3.


Survival after hepatic resection of colorectal cancer metastases: a national experience.

Robertson D, Stukel T, Gottlieb D, Sutherland J, Fisher E Cancer. 2009; 115(4):752-9.

PMID: 19130462 PMC: 2740982. DOI: 10.1002/cncr.24081.